AGP Executive Report
Last update: 12 hours agoNew Oral GLP-1 Push for Diabetes: A 16-week phase 2 trial found once-daily oral HRS-7535 (a nonpeptide GLP-1 receptor agonist) added to metformin improved glycemic control and produced modest weight reduction in type 2 diabetes, with a safety profile consistent with other GLP-1s. Aging Skin, Injectables Demand: Multiple industry updates focus on wrinkle and tear-trough treatments, mesotherapy, and “skin booster” trends—plus guidance on choosing injectables and sourcing safer hyaluronic acid fillers. Regenerative Aesthetics Spotlight: At IMCAS Paris and AMWC Monaco, PCL biostimulators and next-gen tissue restoration themes drew attention, with emphasis on predictable results and certified manufacturing. MASLD & Metabolic Herbs: A systematic review/network meta-analysis in adults with MASLD linked several herbal products (like green tea, curcumin, silymarin, artichoke leaf, flaxseed, and garlic-based preparations) to modest improvements in triglycerides, LDL, fasting glucose, BMI, and insulin resistance—without consistent A1c benefit. Heatwave Crop Risk (Health Link): China’s heatwave raises concerns for corn, rice, and cotton damage and crop disease risk, with potential downstream effects on food security and nutrition.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
